VIVA 2015 Roundup: Medtronic touts Valiant stent graft, PAD stent-treatment data

Medtronic (NYSE:MDT) this week presented data from 2 studies of its stent systems and announced a new study of its In.Pact Admiral drug-coated balloon. The announcements were made at the VIVA physicians annual conference in Las Vegas, Nev. The Fridley, Minn.-based medical giant presented data from a 2-year clinical trial of its Valian Captivia thoracic stent graft system for treating type B aortic dissections, reporting safety and efficacy at 2-years. Data from the 2-year follow up of the 35-patient FDA approved IDE trial reported no post-index procedure ruptures or conversions, device related adverse events or loss of stent graft integrity or collapse. At 24-months, true-lumen diameter in the stented region remained stable or increased in 85.7% of patients, false-lumen diameter remained stable or decreased in 78.6% .  The study reported that false lumen was partially or completely thrombosed in 70.4% of patients, Medtronic said. “There is a growing body of evidence supporting the use of thoracic endovascular aortic repair as a safe and effective treatment for patients with acute type B aortic dissections. The Valiant Captivia system has continued to produce positive patient outcomes at 2 years,” Dr. Ali Azizzadeh of the University of Texas Health Science Center said in a prepared statement. Medtronic presented data from a 9-month trial comparing the use of self-expanding stents and balloon expanding stents for treating peripheral artery disease in patients w...
Source: Mass Device - Category: Medical Equipment Authors: Tags: Cardiovascular Clinical Trials Abbott Avinger Boston Scientific C.R. Bard Cook Medical Medtronic Spectranetics Corp. TriVascular TVA Medical Vascular Dynamics Vascular Interventional Advances (VIVA) Source Type: news